Sarepta's Elevidys shows benefit in older Duchenne patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 18.18 -0.38 (2.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.56 | 52 Week High | $63.73 | |||
| Open | $18.40 | 52 Week Low | $8.00 | |||
| Day High | $18.94 | P/E | N/A | |||
| Day Low | $18.12 | EPS | $-5.69 | |||
| Volume | 1,235,360 | |||||
